Clinical Trials

The Tumor Immunotherapy Program has a number of studies that are currently recruiting patients. For information about how to be referred to one of these studies, please contact us.

Currently Recruiting

  • ADP-0044-002

    A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

    Eligible Tumour Type(s): Sarcoma
    Principal Investigator: Dr. Albiruni Razak
    NCT#: NCT04044768

    https://clinicaltrials.gov/ct2/show/NCT04044768

  • IOV-COM-202

    A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

    Eligible Tumour Type(s): Metastatic Melanoma, Non-small Cell Lung Cancer
    Principal Investigator: Dr. Adrian Sacher
    NCT#: NCT03645928

    https://clinicaltrials.gov/ct2/show/NCT03645928

  • IMCnyeso-101

    A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer 

    Eligible Tumour Type(s): Solid Cancer
    Principal Investigator: Dr. Marcus Butler
    NCT#: NCT03515551

    https://clinicaltrials.gov/ct2/show/NCT03515551

  • GSK208467

    Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO) 

    Eligible Tumour Type(s): Sarcoma
    Principal Investigator: Dr. Albiruni Razak
    NCT#: NCT03967223

    https://clinicaltrials.gov/ct2/show/NCT03967223

  • GSK208750

    Long-Term Follow-Up (LTFU) of Participants Treated with GSK Adoptive Cell Therapies

    Eligible Tumour Type(s): Solid Cancer
    Principal Investigator: Dr. Adrian Sacher
    NCT#: NCT03391778

    https://www.clinicaltrials.gov/ct2/show/NCT03391778

  • SQZ-PBMC-HPV-101

    A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

    Eligible Tumour Type(s): Solid Cancer
    Principal Investigator: Dr. Neesha Dhani
    NCT#: NCT04084951

    https://clinicaltrials.gov/ct2/show/NCT04084951

  • CRSP-ONC-003

    A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation

    Eligible Tumour Type(s): Renal Cell Carcinoma
    Principal Investigator: Dr. Adrian Sacher
    NCT#: NCT04438083

    https://clinicaltrials.gov/ct2/show/NCT04438083

  • TCR2-18-01

    A Phase 1/2 Single Arm Open-Label Clinical Trial of Tc-210 T Cells In Patients with Advanced Mesothelin-Expressing Cancer

    Eligible Tumour Type(s): Solid Cancer
    Principal Investigator: Dr. Marcus Butler
    NCT#: NCT03907852

    https://clinicaltrials.gov/ct2/show/NCT03907852

  • IOV-LUN-202

    A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer 

    Eligible Tumour Type(s): Non-small Cell Lung Cancer
    Principal Investigator: Dr. Adrian Sacher
    NCT#: NCT04614103

    https://clinicaltrials.gov/ct2/show/NCT04614103

  • TAC01-HER2-03

    A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2) 

    Eligible Tumour Type(s): Solid Cancer
    Principal Investigator: Dr. Adrian Sacher
    NCT#: NCT04727151

    https://clinicaltrials.gov/ct2/show/NCT04727151

Pages